Inhibitory effects of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators

Oncology Research

Volumn 10, Issue 11-12, 1998, Pages 575-589

  Seppänen, Marjo ^a,c   Henttinen, Tiina ^b,c   Lin, Lin ^b,d   Punnonen, Juha ^b   Grénman, Seija ^b   Punnonen, Reijo ^a,b   Vihko, Kimmo K ^e,f  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b Department of Obstetrics and Gynecology ^*  (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cytokines; Endometrial adenocarcinoma cells; Ovarian carcinoma cells; Transcription regulators

Indexed keywords

CYTOKINE; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ADENOCARCINOMA; AGED; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG EFFECT; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY;

ADENOCARCINOMA; AGED; CELL DIVISION; CYTOKINES; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NF-KAPPA B; OVARIAN NEOPLASMS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0032249062     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Richters, C.; Burger, C.; van de Loosdrecht, A.; van Rijswijk, R.; CalamE, W.; Bleker, O.; Vermorken, J.; Kenemans, P.; Beelen, R. The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumour necrosis factor-α treatment. Cancer Lett. 68:25-31; 1993.
2. Tabibzadeh, S. Evidence of T-cell activation and potential cytokine action in human endometrium. J. Clin. Endocrinol. Metab. 71:645-649; 1990.
3. Tabibzadeh, S. Human endometrium: An active site of cytokine production and action. Endocr. Rev. 12:272-290; 1991.
4. Tabibzadeh, S.; Sun, X.; Kong, Q.; Kasnic, G.; Miller, J.; Satyaswaroop, P. Induction of a polarized micro-environment by human T cells and interferon-gamma in three-dimensional spheroid cultures of human endometrial epithelial cells. Hum. Reprod. 8:182-192; 1993.
5. Tabibzadeh, S. Cytokines and the hypothalamic-pituitary-ovarian-endometrial axis. Hum. Reprod. 9:947-967; 1994.
6. Garcia, F.; Chen, H-L.; Yang, Y.; Pace, J.; Hu, X-L.; Hunt, J. Tumor necrosis factor-α mRNA and protein in endometrial tumors: Analysis by in situ hybridization and immunocytochemistry. Hum. Pathol. 25:1324-1331; 1994.
7. Boyd, J.; Kaufman, D. Expression of transforming growth factor Pi by human endometrial carcinoma cell line: Inverse correlation with effects on growth rate and morphology. Cancer Res. 50:3394-3399; 1990.
8. Powell, C.; Horuchi, T.; Kao, M-S.; Collins, J. Interferon alfa activates a lytic mechanism in ovarian and cervical carcinoma cells. Am. J. Obstet. Gynecol. 169:661-667; 1993.
9. Salmon, S.; Liu, R. Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors. J. Clin. Oncol. 7:1346-1350; 1989.
10. 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. Int. J. Cancer 52:766-770; 1992.
11. Mathieu, C.; Jozan, S.; Mazars, P.; Come, M.; Moisand, A.; Valette, A. Density dependent induction of apoptosis by transforming growth factor-β1 in a human ovarian carcinoma cell line. Exp. Cell Res. 216:13-20; 1995.
12. Angel, P.; Karin, M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem. Biophys. Acta 1072:129-157; 1991.
13. 125I-deoxyuridine uptake by human and chicken lymphocytes in the quantitation of mitogenic response. J. Immunol. Methods 6:73-82; 1974.
14. Vihko, K. K.; Seppänen, M.; Henttinen, T.; Punnonen, J.; Grenman, S.; Punnonen, R. Regulation of UM-SCV-1A and UM-SCV-6 vulvar carcinoma cell proliferation by cytokines. Cancer Immunol. Immunother. 43:368-374; 1997.
15. Smith, C.; Williams, G. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 337:181-184; 1989.
16. Andrews, N.; Faller, D. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:249; 1991.
17. Itri, L. The interferons. Cancer 70:940-945; 1992.
18. Miller, A.; McBride, W.; Hunt, K.; Economou, J. Cytokine-mediated gene therapy for cancer. Ann. Surg. Oncol. 1:436-450; 1994.
19. Powell, C.; Horuchi, T.; Kao, M.-S.; Collins, J. Interferon alfa activates a lytic mechanism in ovarian and cervical carcinoma cells. Am. J. Obstet. Gynecol. 169:661-667; 1993.
20. Kost, E.; Herzog, T.; Adler, L.; Williams, S.; Mutch, D. The role of tumor necrosis factor receptors in tumor necrosis factor-α-mediated cytolysis of ovarian cancer cell lines. Am. J. Obstet. Gynecol. 174:145-153; 1996.
21. Hammond, M.; Oh, S-T.; Anners, J.; Surrey, E.; Halme, J. The effect of growth factors on the proliferation of human endometrial stromal cells in culture. Am. J. Obstet. Gynecol. 168:1131-1138; 1993.
22. Tang, X-M.; Zhao, Y.; Rossi, M.; Abu-Rustum, R.; Ksander, G.; Chegini, N. Expression of transforming growth factor-β (TGFβ) isoforms and TGFβ type 2 receptor messenger ribonucleic acid and protein, and the effect of TGFβs on endometrial stromal cell growth and protein degration in vitro. Endocrinology 135:450-459; 1994.
23. Zhu, Y-M.; Bradbury, D.; Russell, N. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br. J. Cancer 69:468-472; 1994.
24. Eliopoulos, A. G.; Kerr, D. J.; Herod, J.; Hodgkins, L.; Krajewski, S.; Reed, J. C.; Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 11:1217-1228; 1995.
25. 1. Cancer Res. 55:944-948; 1995.
26. Mayo, M.; Wang, C-Y.; Cogswell, P.; Rogers-Graham, K.; Lowe, S.; Der, C.; Baldwin, A., Jr. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812-1815; 1997.
27. Baldwin, A., Jr. The NF-κB and IκB proteins: New discoveries and insights. Annu. Rev. Immunol. 14:649-681; 1996.
28. Bours, V.; Dejardin, E.; Goujon-Letawe, F.; Merville, M.; Castronovo, V. The NF-κB transcription factor and cancer: High expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem. Pharmacol. 47:145-149; 1994.
29. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D.; Goulet, R., Jr.; Sledge, G., Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17:3629-3639; 1997.
30. Sovak, M.; Bellas, R.; Kim, D.; Zanieski, G.; Rogers, A.; Traish, A.; Sonenshein, G. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100:2952-2960; 1997.
31. 1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10:1492-1497; 1990.
32. Sikora, E.; Grassilli, E.; Bellesia, E.; Troiano, L.; Franceschi, C. Studies of the relationship between cell proliferation and cell death. AP-1 DNA-binding activity during concavalin A-induced proliferation or dexamethasone-induced apoptosis of rat thymocytes. Biochem. Biophys. Res. Commun. 192:386-393; 1993.
33. Dixit, V.; Marks, R.; Sarma, V.; Prochownik, E. The antimitogenic action of tumor necrosis factor is accociated with increased AP-1/c-jun proto-oncogene transcription. J. Biol. Chem. 264:16905-16909; 1989.
34. Brach, M.; Gruss, H.; Sott, C.; Herrmann, F. The mitogenic response to tumor necrosis factor alpha requires c-Jun/AP-1. Mol. Cell. Biol. 13:4284-4290; 1993.
35. Lewis, G.; Aggarwal, B.; Eessalu, T.; Sugarman, B.; Shepard, H. Modulation of the growth of transformed cells by human tumor necrosis factor-α and interferon-γ. Cancer Res. 47:5382-5385; 1987.
36. Powell, C.; Manning, K.; Collins, J. Interferon-α (IFNα) induces a cytolytic mechanism in ovarian carcinoma cells through a protein kinase C-dependent pathway. Gynecol. Oncol. 50:208-214; 1993.
37. Welander, C. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs. Cancer 59:617-619; 1987.
38. Pujade-Lauraine, E.; Guastalla, J. P.; Colombo, N.; Devillier, P.; Francois, E.; Fumoleau, P.; Monnier, A.; Nooy, M.; Mignot, L.; Bugat, R.; Margues, C.; Mousseau, M.; Netter, G.; Maloisel, F.; Larbaoui, S.; Brandely, M. Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second look laparotomy. J. Clin. Oncol. 14:4923-4928; 1990.
39. Marth, C.; Cronauer, M. V.; Doppier, W.; Öfner, D.; Ullrich, A.; Daxenbichler, U. Effects of interferons on the expression of the proto-oncogene her-2 in human ovarian carcinoma cells. Int. J. Cancer 50:64-68; 1992.
40. Balkwill, F.; Ward, B.; Moodie, E.; Fiers, W. Therapeutic potential of tumor necrosis factor-α and γ-interferon in experimental human ovarian cancer. Cancer Res. 47:4755-4758; 1987.
41. Lebel-Binay, S.; Laguerre, B.; Quintin-Colonna, F.; Conjeaud, H.; Magazin, M.; Miloux, B.; Pecceu, F.; Caput, D.; Ferrara, P.; Fradelizi, D. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur. J. Immunol. 25:2340-2348; 1995.
42. Steward, W. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 342:153-157; 1993.
43. Dranoff, G.; Jaffee, E,.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Lackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R. Vaccination with irradiated tumor cells engineered to secrete mu-rine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539-3543; 1993.
44. Shireen, A.; Jabbar, A.; Hoffbrand, V.; Wickremasinghe, G. Regulation of transcription factors NF-κB and AP-1 following tumour necrosis factor-α treatment of cells from chronic B cell leukaemia patients. Br. J. Hematol. 86:496-504; 1994.
45. Kelliher, M.; Grimm, S.; Ishida, Y.; Kuo, F.; Stanger, B.; Leder, P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8:297-303; 1998.